Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...

Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the U.S., more often people who are Black and more women than men, particularly when it causes chronic skin disease.

Campbell said avoiding stress and taking great care of her health helped her go into remission Tisha Campbell is speaking out ...

Clinical-stage biotech company aTyr Pharma (ATYR) has seen a significant 24% increase in stock value over the past week, as the company posted ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

From the departments of Medicine, Veterans Administration Hospital, George Washington University and Georgetown University. Washington, D. C. (address reprint requests to Dr. Becker at 50 Irving ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

Considering taking supplements to treat sarcoidosis? Below is a list of common natural remedies used to treat or reduce the symptoms of sarcoidosis. Follow the links to read common uses ...

Tyr Pharma Inc (ATYR) reports robust financial health and significant progress in its pivotal phase three study for pulmonary ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

“As we look to position efzofitimod as a potential chronic, maintenance therapy for patients with pulmonary sarcoidosis that can reduce or eliminate the use of oral corticosteroids, we are ...